DBV Technologies Reports Full Year 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DBV Technologies Reports Full Year 2014 Financial Results

BAGNEUX, France, March 25, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today its full year 2014 results. The audit procedures on the 2014 consolidated financial statements were completed by statutory auditors. The issuance of the audit report is ongoing.

Full year 2014 results

Selected financial information (IFRS consolidated financial statements)

In million euros 2014 2013
Total income 4.76 3.83
Research and development expenses (21.14) (17.37)
General and administrative expenses (8.12) (6.31)
Operating profit (loss) (24.64) (19.95)
Net profit (loss) (24.01) (19.31)
EPS (in € per share) (1.49) (1.42)
Net cash flows from operating activities (20.56) (13.25)
Net cash flows from financing activities 96.81 16.24
Net cash flows 75.15 1.57
Cash and cash equivalents at closing 114.58 39.40

The Company's total income amounted to €4,761,522 and €3,826,313 in 2014 and 2013, respectively.  These revenues were primarily generated by Research Tax Credits, and to a lesser extent, by sales of Diallertest ® , as well as by subsidies received within the framework of research projects conducted by the Company. Sales of Diallertest® increased to €210,759 in 2014 compared with €181,800 a year earlier, with the overall demand remaining stable year-over-year.

Research and development expenses increased by 22% to €21,143,442 compared with €17,366,538 a year earlier. This increase reflects an intense R&D activity, both on the pre-clinical research and clinical development fronts, and the reinforcement of teams dedicated to R&D, in an effort to drive all on-going programs.

General and administrative expenses include mainly management and administrative personnel costs, structural costs related to the headquarters, and external expenses such as audit, legal and consultant fees. In 2014, general and administrative expenses increased to €8,117,664 compared with €6,309,750 a year earlier. This increase resulted notably from certain non-recurring compensation items, the grant of performance shares, and the ramp-up of US activities, notably the listing on the Nasdaq.

The net loss in 2014 amounted to €(24,011,880) compared with €(19,306,416) in 2013. The loss per share issued (based on the weighted average number of shares outstanding over the period) amounted to €(1.49) and €(1.42) for 2014 and 2013, respectively.

Net cash flows from operational activities in 2014 and 2013 stood at €(20,559,652) and €(13,253,215), respectively, primarily fuelled by increasing efforts engaged in R&D.

Net cash flows from financing activities increased to €96,808,306 in 2014 compared with €16,235,770 a year earlier, following the receipt of the net proceeds of €93.7 million related to the capital raise completed in October 2014.

DBV Technologies plans to announce its topline and cash position for the first three months on April 29, 2015.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com   

Forward Looking Statements

This press release contains forward-looking statements, including statements reflecting management's expectations for future financial and operational performance and business outlook; and statements regarding our research and development efforts and the commercial potential of our product candidates generally.   These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results.  A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's prospectus filed with the SEC on October 22, 2014 and future filings and reports by the Company.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.  

DBV Technologies Contacts
Susanna Mesa
VP Finance, US Investor Relations & Strategy
Tel. : +1 917-346-3447
susanna.mesa@dbv-technologies.com
Nathalie Donne
Director, Corporate Communication & Business Development
Tel. : +33(0)1 55 42 78 72
nathalie.donne@dbv-technologies.com
DBV Technologies IR and Media Contacts
Marion Janic
US Media Relations
Rooney & Associates
Tel. : +1-212-223-4017
mjanic@rooneyco.com
 

Full Year Results http://hugin.info/156437/R/1905943/678390.pdf

HUG#1905943

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 15

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 34

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading

Top 5 Most Recently Viewed Articles

Carvana's Stock Peaks at $187.37 Amid Renewed Investor Confidence

Updated Category News Views 79

Carvana's Impressive Stock Surge to 52-Week High Recently, Carvana Co (NYSE: CVNA) achieved a remarkable milestone by hitting a 52-week high of $187.37. This surge highlights a robust recovery for the online used car retailer, whose stock has skyrocketed by an impressive 377.82% over the past year. This surge in stock price signifies renewed investor confidence in...

Continue Reading
ABM Industries Closes Q3 with Strong Earnings and Growth Boost

Updated Category News Views 133

ABM Industries Reports Strong Q3 Earnings ABM Industries (NYSE: ABM) saw its share price jump nearly 7% following the announcement of its third quarter earnings, which exceeded analyst expectations and prompted an upgrade to its full-year guidance. This positive outcome underscores the company's resilience in a challenging market landscape. Robust Financial Performance In...

Continue Reading
Transforming Senior Care: Click Holdings Embraces Cryptocurrency

Updated Category News Views 144

Innovative Strategies in Senior Care by Click Holdings Limited Click Holdings Limited (NASDAQ: CLIK) is making headlines with its groundbreaking approach to enhancing senior care services. Based in Hong Kong, this company combines cutting-edge human resources solutions with innovative cryptocurrency strategies, aiming to redefine how care services operate in an evolving...

Continue Reading
Cypress Creek and Meta Join Forces for Major Solar Project

Updated Category News Views 360

Cypress Creek and Meta's Renewable Energy Partnership In an exciting development, Cypress Creek Renewables and Meta have reached a significant milestone through their new Environmental Attribute Purchase Agreement (EAPA). This agreement is set to pave the way for the construction of a massive 505MWdc solar facility named Hanson Solar. With a capacity of 396MWac, this...

Continue Reading
The Shipyard Sets Sail with San Diego Headquarters Expansion

Updated Category News Views 462

The Shipyard Sets Sail with San Diego Headquarters Expansion The Shipyard, one of the fastest-growing independent marketing agencies in the nation, has announced an exciting development. The agency is expanding its operations by opening a new headquarters located in downtown San Diego at 185 West F Street. This move signifies a deepening of their commitment to California,...

Continue Reading